Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
AIMS No randomized trial has compared SGLT2 inhibitors with finerenone in chronic kidney disease (CKD) with Type 2 diabetes. We estimated their comparative cardiorenal efficacy and safety. MATERIALS AND METHODS MEDLINE, Embase, CENTRAL and trial registries were searched from inception to August 2026 for placebo-contr...